GSK (NYSE:GSK) Stock Price Up 3.5% – Here’s Why

Shares of GSK PLC Sponsored ADR (NYSE:GSK) rose 3.5% on Wednesday. The company traded as high as $47.87 and last traded at $47.8950. 3,048,071 shares changed hands during trading, a decline of 32% from the average session volume of 4,460,884 shares. The stock had previously closed at $46.27.

Key Headlines Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK and the University of Oxford have dosed the first patient in a clinical trial for an experimental treatment for ulcerative colitis. The study is an early-stage milestone that expands GSK’s immunology and gastrointestinal pipeline, although any commercial benefit remains several years away. First Patient Dosed in GSK-Oxford Colitis Trial
• Positive Sentiment: Recent analysis highlights GSK’s global restructuring and greater focus on biologics in the United States as potentially important strategic catalysts. Investors may view the moves as efforts to concentrate capital on higher-growth medicines and strengthen the company’s long-term competitive position. Global Restructuring and US Biologics Bet Could Be a Game Changer for GSK
• Neutral Sentiment: The reported Belgium workforce reduction is part of a broader, three-year restructuring plan. While the changes could eventually lower operating costs, the scale, timing, and financial impact of the program remain subject to consultation and implementation. GSK to Cut Up to 1,217 Jobs in Belgium, L’Echo Says
• Negative Sentiment: GSK reportedly plans to eliminate up to 1,217 jobs in Belgium, including positions connected with its vaccine operations. The announcement raises concerns about employee disruption, restructuring charges, and possible pressure on manufacturing or research execution in the near term. Pharmaceutical Giant GSK to Eliminate 1,200 Jobs in Belgium

Analysts Set New Price Targets

A number of brokerages have commented on GSK. Jefferies Financial Group reiterated a “buy” rating on shares of GSK in a report on Monday, September 28th. JPMorgan Chase & Co. reissued a “sell” rating on shares of GSK in a research report on Thursday, October 1st. Citigroup initiated coverage on shares of GSK in a report on Friday, July 24th. They issued a “neutral” rating on the stock. Sanford C. Bernstein reaffirmed a “buy” rating on shares of GSK in a research report on Sunday, August 2nd. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of GSK in a research report on Tuesday, October 6th. Four investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $55.33.

GSK Price Performance

The firm has a market cap of $99.23 billion, a PE ratio of 15.34, a price-to-earnings-growth ratio of 2.15 and a beta of 0.33. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81. The stock has a 50 day moving average price of $49.68 and a two-hundred day moving average price of $51.65.

GSK (NYSE:GSK) last announced its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.27 by $0.09. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. GSK’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm posted $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, equities analysts expect that GSK PLC Sponsored ADR will post 4.78 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 8th. Stockholders of record on Friday, August 14th were paid a dividend of $0.4515 per share. The ex-dividend date was Friday, August 14th. This is an increase from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 annualized dividend and a dividend yield of 3.7%. GSK’s payout ratio is presently 55.31%.

Hedge Funds Weigh In On GSK

Several hedge funds have recently made changes to their positions in GSK. Security National Bank of SO Dak purchased a new position in GSK in the 2nd quarter worth $38,000. Trust Co. of Vermont purchased a new stake in GSK during the 2nd quarter valued at about $54,000. Philadelphia Investment Partners LLC purchased a new stake in GSK during the 2nd quarter valued at about $70,000. Ancora Advisors LLC acquired a new position in shares of GSK in the second quarter valued at about $71,000. Finally, Bogart Wealth LLC increased its holdings in shares of GSK by 15.3% in the first quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock valued at $83,000 after purchasing an additional 200 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.